2023年度 研究業績

Quaternization of high molecular weight chitosan for increasing intestinal drug absorption using Caco-2 cells as an in vitro intestinal model.
Wongwanakul R, Aueviriyavit S, Furihata T, Gonil P, Sajomsang W, Maniratanachote R, Jianmongkol S.
Sci Rep. 2023;13(1):7904.

Calculation of Human Melatonin Partial Metabolic Clearance in Healthy Adult Volunteers for Investigation of a Novel in Vivo CYP1A2 Phenotyping Method: A Pilot Study.
Ohki S, Ogawa S, Takano H, Shimazaki H, Fukae M, Furihata T, Shibasaki H, Yokokawa A.
Biol Pharm Bull. 2023;46(5):736-740.

Comparative study of stable isotope-labeled internal standard substances for the LC-MS/MS determination of the urinary excretion of melatonin.
Shimazaki H, Ogawa S, Takano H, Ohki S, Fukae M, Furihata T, Shibasaki H, Yokokawa A.
Med Mass Spectr. 2023;7(1): DOI: 10.24508/mms.2023.06.004.

2022年度 研究室の業績

Rapid and Stable Formation Method of Human Astrocyte Spheroid in a High Viscous Methylcellulose Medium and Its Functional Advantages.
Tao F, Kitamura K, Hanada S, Sugimoto K, Furihata T, Kojima N.
Bioengineering. 2023;10(3):349.

Usefulness of a humanized tricellular static transwell blood-brain barrier model as a microphysiological system for drug development applications. - A case study based on the benchmark evaluations of blood-brain barrier microphysiological system.
Nakayama-Kitamura K, Shigemoto-Mogami Y, Toyoda H, Mihara I, Moriguchi H, Naraoka H, Furihata T, Ishida S, Sato K.
Regen Ther. 2023, 22:192-202.

siRNA delivery to lymphatic endothelial cells via ApoE-mediated uptake by lipid nanoparticles.
Sakurai Y, Yoshikawa K, Arai K, Kazaoka A, Aoki S, Ito K, Nakai Y, Tange K, Furihata T, Tanaka H, Akita H.
J Control Release. 2022, 353:125-133.

Influence of Anticoagulants and Storage Conditions During Blood Sample Collection on Determination of the 6β-hydroxycortisol/cortisol Ratio by LC-MS/MS.
Shibasaki H, Yokokawa A, Furihata T.
BUNSEKI KAGAKU. 2022, 71(6):357-363.

The impaired distribution of adenosine deaminase isoenzymes in multiple sclerosis plasma and cerebrospinal fluid.
Kutryb-Zajac B, Kawecka A, Caratis F, Urbanowicz K, Braczko A, Furihata T, Karaszewski B, Smolenski RT, Rutkowska OA.
Front. Mol. Neurosci., 2022,15:998023.

Generation of a Human Conditionally Immortalized Cell-based Multicellular Spheroidal Blood-Brain Barrier Model for Permeability Evaluation of Macromolecules.
Isogai R, Okamoto A, Morio H, Kitamura K, Furihata T.
Bio Protoc. 2022; 12(15):e4465.Bio protocol

Human Immortalized Cell-Based Blood-Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules.
Kitamura K, Okamoto A, Morio H, Isogai R, Ito R, Yamaura Y, Izumi S, Komori T, Ito S, Ohtsuki S, Akita H, Furihata T.
Mol Pharm. 2022; 19(8):2754-2764.

cGAS and DDX41-STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model.
Tan HY, Yong YK, Xue YC, Liu H, Furihata T, Shankar EM, Ng CS. iScience. 2022;25(6):104404.

Development of a three-dimensional blood-brain barrier network with opening capillary structures for drug transport screening assays.
Piantino M, Kang DH, Furihata T, Nakatani N, Kitamura K, Shigemoto-Mogami Y, Sato K, Matsusaki M.
Mater Today Bio. 2022; 15: 100324.

Effects of 11β-hydroxysteroid dehydrogenase 2 activity on the prediction accuracy of plasma unbound cortisol concentration based on salivary cortisol.
Yokokawa A, Kitano A, Tanaka D, Higashi K, Yanada S, Shimizu K, Furihata T, Shibasaki H.
Med Mass Spectr, 2022; 6(1): 45-51.

Development and Validation of an LC-MS/MS-Based Method for Quantifying Urinary Endogenous 6-Hydroxymelatonin.
Ohki S, Kunimatsu M, Ogawa S, Takano H, Furihata T, Shibasaki H, Yokokawa A.
Chem Pharm Bull. 2022; 70(5): 375-382.

In Vitro-In Vivo Correlation of Blood-Brain Barrier Permeability of Drugs: A Feasibility Study Towards Development of Prediction Methods for Brain Drug Concentration in Humans.
Ito R, Morio H, Baba T, Sakaguchi Y, Wakayama N, Isogai R, Yamaura Y, Komori T, Furihata T.
Pharm Res. 2022, 39(7):1575-1586.

2021年度 研究室の業績

Functional analysis of human brain endothelium using a microfluidic device integrating a cell culture insert
Miura S, Morimoto Y, Furihata T, Takeuchi S.
APL Bioengineering. 2022, 6, 016103.

Astrocyte Control of Zika Infection Is Independent of Interferon Type I and Type III Expression.
Das M, Smith ML, Furihata T, Sarker S, O'Shea R, Helbig KJ.
Biology (Basel). 2022;11(1):143.

Evaluating a Targeted Cancer Therapy Approach Mediated by RNA trans-Splicing In Vitro and in a Xenograft Model for Epidermolysis Bullosa-Associated Skin Cancer.
Woess K, Sun Y, Morio H, Stierschneider A, Kaufmann A, Hainzl S, Trattner L, Kocher T, Tockner B, Leb-Reichl V, Steiner M, Brachtl G, South AP, Bauer JW, Reichelt J, Furihata T, Wally V, Koller U, Piñón Hofbauer J, Guttmann-Gruber C.
Int J Mol Sci. 2022;23(1):575.

Dried blood spots analysis of 6β-hydroxycortisol and cortisol using liquid chromatography/tandem mass spectrometry for calculating 6β-hydroxycortisol to cortisol ratio.
Hirano R, Yokokawa A, Furihata T, Shibasaki H.
J Mass Spectrom. 2021;56(12):e4790.

Haploinsufficiency of microglial MyD88 ameliorates Alzheimer's pathology and vascular disorders in APP/PS1-transgenic mice.
Quan W, Luo Q, Hao W, Tomic I, Furihata T, Schulz-Schäffer W, Menger MD, Fassbender K, Liu Y.
Glia. 2021, 69(8):1987-2005.

Development, characterization and potential applications of a multicellular spheroidal human blood-brain barrier model integrating three conditionally immortalized cell lines.
Kitamura K, Umehara K, Ito R, Yamaura Y, Komori T, Morio H, Akita H, Furihata T.
Biol Pharm Bull. 2021, 44(7):984-991.
Selected as a Featured article in this journal!

Effects of islatravir (4'-ethynyl-2-fluoro-2'-deoxyadenosine or EFdA) on renal tubular cells and islatravir's interactions with organic anion transporters.
Kaneko M, Reien Y, Morio H, Fukuuchi T, Kaneko K, Hirayama Y, Hashimoto H, Kuwata N, Mitsuya H, Anzai N.
J Pharmacol Sci. 2021;146(2):82-87.

Conserved lysine residues in decorin binding proteins of Borrelia garinii are critical in adhesion to human brain microvascular endothelial cells.
Pietikäinen A, Åstrand M, Cuellar J, Glader O, Elovaara H, Rouhiainen M, Salo J, Furihata T, Salminen TA, Hytönen J.
Mol Microbiol. 2021, 115(6):1395-1409.


Effect of UGT1A1, CYP3A and CES Activities on the Pharmacokinetics of Irinotecan and its Metabolites in Patients with UGT1A1 Gene Polymorphisms.
Yokokawa A, Kaneko S, Endo S, Minowa Y, Ayukawa H, Hirano R, Nagashima F, Naruge D, Okano N, Kobayashi T, Kawai K, Furuse J, Furuta T, Shibasaki H.
Eur J Drug Metab Pharmacokinet. 2021, 46(2):317-324..

Ischemic stroke disrupts the endothelial glycocalyx through activation of proHPSE via acrolein exposure.
Ko K, Suzuki T, Ishikawa R, Hattori N, Ito R, Umehara K, Furihata T, Dohmae N, Linhardt RJ, Igarashi K, Toida T, Higashi K.
J Biol Chem. 2020 Oct 30:jbc.RA120.015105. doi: 10.1074/jbc.RA120.015105.

Identification of AR-V7 downstream genes commonly targeted by AR/AR-V7 and specifically targeted by AR-V7 in castration resistant prostate cancer.
Sugiura M, Sato H, Okabe A, Fukuyo M, Mano Y, Shinohara KI, Rahmutulla B, Higuchi K, Maimaiti M, Kanesaka M, Imamura Y, Furihata T, Sakamoto S, Komiya A, Anzai N, Kanai Y, Luo J, Ichikawa T, Kaneda A.
Transl Oncol. 2020;14(1):100915.

Interstitial flow regulates in vitro three-dimensional self-organized brain micro-vessels.
Figarol A, Piantino M, Furihata T, Satoh T, Sugiura S, Kanamori T, Matsusaki M.
Biochem Biophys Res Commun. 2020, in press.

NLRP3 Is Involved in the Maintenance of Cerebral Pericytes.
Quan W, Luo Q, Tang Q, Furihata T, Li D, Fassbender K, Liu Y.
Front. Cell. Neurosci. 2020;14:276. doi: 10.3389/fncel.2020.00276. eCollection 2020.

In vitro self-organized three-dimensional model of the blood-brain barrier microvasculature.
Figarol A, Naka Y, Shigemoto-Mogami Y, Furihata T, Sato K, Matsusaki M.
Biomed Mater. 2020, in press.

JPH203, a newly developed anti-cancer drug, shows a preincubation inhibitory effect on L-type amino acid transporter 1 function.
Okunushi K, Furihata T, Morio H, Muto Y, Higuchi K, Kaneko M, Otsuka Y, Ohno Y, Watanabe Y, Reien Y, Nakagawa K, Sakamoto S, Wakashin H, Shimojo N, Anzai N.
J Pharmacol Sci. 2020;144(1):16-22.

Midazolam Intoxication in a Premature Neonate.
Endo M, Hirano R, Shibasaki H, Yokokawa A, Furuta T, Abe K, Morita K, Tanaka S, Hirano T, Sakurai M, Mizuno K.
Clin Ther. 2020;42(5):946-951.



Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma.
Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T.
Sci Rep. 2020 Jan 28;10(1):1292. doi: 10.1038/s41598-020-58136-x.

Characterization of the expression of LAT1 as a prognostic indicator and a therapeutic target in renal cell carcinoma.
Higuchi K, Sakamoto S, Ando K, Maimaiti M, Takeshita N, Okunushi K, Reien Y, Imamura Y, Sazuka T, Nakamura K, Matsushima J, Furihata T, Ikehara Y, Ichikawa T, Anzai N.
Sci Rep. 2019;9(1):16776. doi: 10.1038/s41598-019-53397-7.

A Human Immortalized Cell-Based Blood-Brain Barrier Triculture Model: Development and Characterization as a Promising Tool for Drug-Brain Permeability Studies.
Ito R, Umehara K, Suzuki S, Kitamura K, Nunoya KI, Yamaura Y, Imawaka H, Izumi S, Wakayama N, Komori T, Anzai N, Akita H, Furihata T.
Mol Pharm. 2019 Oct 15. doi: 10.1021/acs.molpharmaceut.9b00519. [Epub ahead of print]
The protocol can be found here.

Indirect activation of constitutive androstane receptor in three-dimensionally cultured HepG2 cells.
Yokobori K, Azuma I, Chiba K, Akita H, Furihata T, Kobayashi K.
Biochem Pharmacol. 2019;168:26-37.

Sodium-coupled monocarboxylate transporter 1 interacts with the RING finger- and PDZ domain-containing protein PDZRN3.
Otsuka Y, Furihata T, Nakagawa K, Ohno Y, Reien Y, Ouchi M, Wakashin H, Tsuruoka S, Anzai N.
J Physiol Sci. 2019, in press.

Large-Scale Quantitative Comparison of Plasma Transmembrane Proteins between Two Human Blood-Brain Barrier Model Cell Lines, hCMEC/D3 and HBMEC/ciβ.
Masuda T, Hoshiyama T, Uemura T, Hirayama-Kurogi M, Ogata S, Furukawa A, Couraud PO, Furihata T, Ito S, Ohtsuki S.
Mol Pharmaceut. 2019;16(5):2162-2171.

Identification of equol-7-glucuronide-4'-sulfate, monoglucuronides and monosulfates in human plasma of 2 equol producers after administration of kinako by LC-ESI-MS.
Obara A, Kinoshita M, Hosoda K, Yokokawa A, Shibasaki H, Ishii K.
Pharmacol Res Perspect. 2019;7(3):e00478.





Sensitive and Simultaneous Quantitation of 6β-Hydroxycortisol and Cortisol in Human Plasma by LC-MS/MS Coupled with Stable Isotope Dilution Method
Ryohei Hirano, Akitomo Yokokawa, Takashi Furuta, Hiromi Shibasaki 
J Mass Spectrom, 53, 665-674 (2018)

Different Response Profiles of Gastrointestinal Cancer Cells to an L-Type Amino Acid Transporter Inhibitor, JPH203.
Muto Y, Furihata T, Kaneko M, Higuchi K, Okunushi K, Morio H, Reien Y, Uesato M, Matsubara H, Anzai N.
Anticancer Res. 2019;39(1):159-165.

Polyamines stimulate the CHSY1 synthesis through the unfolding of the RNA G-quadruplex at the 5'-untraslated region.
Yamaguchi K, Asakura K, Imamura M, Kawai G, Sakamoto T, Furihata T, Linhardt RJ, Igarashi K, Toida T, Higashi K.
Biochem J. 2018;475(23):3797-3812.

Synthesis of novel benzbromarone derivatives designed to avoid metabolic activation.
Ohe T, Umezawa R, Kitagawara Y, Yasuda D, Takahashi K, Nakamura S, Abe A, Sekine S, Ito K, Okunushi K, Morio H, Furihata T, Anzai N, Mashino T.
Bioorg Med Chem Lett. 2018;28(23-24):3708-3711.

Differentiated HASTR/ci35 cells: A promising in vitro human astrocyte model for facilitating CNS drug development studies.
Kitamura K, Ito R, Umehara K, Morio H, Saito K, Suzuki S, Hashimoto M, Saito Y, Anzai N, Akita H, Chiba K, Furihata T.
J Pharmacol Sci. 2018;137(4):350-358.

Cancer-type organic anion transporting polypeptide 1B3 is a target for cancer suicide gene therapy using RNA trans-splicing technology.
Sun Y, Piñón Hofbauer J, Harada M, Wöss K, Koller U, Morio H, Stierschneider A, Kitamura K, Hashimoto M, Chiba K, Akita H, Anzai N, Reichelt J, Bauer JW, Guttmann-Gruber C, Furihata T.
Cancer Lett. 2018;433:107-116.

Development of a Caco-2 Cell Line Carrying the Human Intestine-Type CES Expression Profile as a Promising Tool for Ester-Containing Drug Permeability Studies.
Ishizaki Y, Furihata T, Oyama Y, Ohura K, Imai T, Hosokawa M, Akita H, Chiba K.
Biol Pharm Bull. 2018;41(5):697-706.

In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration.
Tanaka H, Nakatani T, Furihata T, Tange K, Nakai Y, Yoshioka H, Harashima H, Akita H.
Mol Pharmaceutics. 2018;15(5):2060-2067.





Cancer-Type OATP1B3 mRNA in Extracellular Vesicles as a Promising Candidate for a Serum-Based Colorectal Cancer Biomarker.
Morio H, Sun Y, Harada M, Ide H, Shimozato O, Zhou X, Higashi K, Yuki R, Yamaguchi N, Hofbauer JP, Guttmann-Gruber C, Anzai N, Akita H, Chiba K, Furihata T.
Biol Pharm Bull. 2018;41(3):445-449.

Development of a New Conditionally Immortalized Human Liver Sinusoidal Endothelial Cells.
Zhu M, Koibuchi A, Ide H, Morio H, Shibuya M, Kamiichi A, Tsubota A, Anzai N, Akita H, Chiba K, Furihata T.
Biol Pharm Bull. 2018;41(3):440-444.

Soluble CD40 ligand disrupts the blood-brain barrier and exacerbates inflammation in experimental autoimmune encephalomyelitis.
Masuda H, Mori M, Umehara K, Furihata T, Uchida T, Uzawa A, Kuwabara S.
J Neuroimmunol. 2018 Mar 15;316:117-120.

Extracellular Vesicles as Biomarkers for the Detection of a Tumor Marker Gene in Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
Sun Y, Woess K, Kienzl M, Leb-Reichl VM, Feinle A, Wimmer M, Zauner R, Wally V, Luetz-Meindl U, Mellerio JE, Fuentes I, South AP, Bauer JW, Reichelt J, Furihata T, Guttmann-Gruber C, Piñón Hofbauer J.
J Invest Dermatol. 2018 May;138(5):1197-1200.

Characterization of an L-Carnitine Transport System in Murine Photoreceptor Cell Line.
Ohno Y, Otsuka Y, Nohara M, Furihata T, Kuse Y, Itoh Y, Hara H, Anzai N.
Biol Pharm Bull. 2017;40(12):2110-2116.

A New Conditionally Immortalized Human Fetal Brain Pericyte Cell Line: Establishment and Functional Characterization as a Promising Tool for Human Brain Pericyte Studies.
Umehara K, Sun Y, Hiura S, Hamada K, Itoh M, Kitamura K, Oshima M, Iwama A, Saito K, Anzai N, Chiba K, Akita H, Furihata T.
Mol Neurobiol. 2018 Jul;55(7):5993-6006.

Cancer-type OATP1B3 mRNA has the potential to become a detection and prognostic biomarker for human colorectal cancer.
Sun Y, Harada M, Shimozato O, Souda H, Takiguchi N, Nabeya Y, Kamijo T, Akita H, Anzai N, Chiba K, Furihata T.
Biomark Med. 2017 Aug;11(8):629-639.


Functional Expression of Organic Ion Transporters in Astrocytes and Their Potential as a Drug Target in the Treatment of Central Nervous System Diseases.
Furihata T, Anzai N.
Biol Pharm Bull. 2017;40(8):1153-1160.




Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter.
Furihata T, Morio H, Zhu M, Suzuki Y, Ide H, Tsubota A, Fu Z, Anzai N, Chiba K.
Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.

Polyamines release the let-7b-mediated suppression of initiation codon recognition during the protein synthesis of EXT2.
Imamura M, Higashi K, Yamaguchi K, Asakura K, Furihata T, Terui Y, Satake T, Maegawa J, Yasumura K, Ibuki A, Akase T, Nishimura K, Kashiwagi K, Linhardt RJ, Igarashi K, Toida T.
Sci Rep. 2016 Sep 21;6:33549.

Involvement of ESE-3, epithelial-specific ETS factor family member 3, in transactivation of the ABCB1 gene via pregnane X receptor in intestine-derived LS180 cells but not in liver-derived HepG2 cells.
Kameyama N, Kobayashi K, Shimizu S, Yamasaki Y, Endo M, Hashimoto M, Furihata T, Chiba K.
Drug Metab Pharmacokinet. 2016 Oct;31(5):340-348.


古田  隆,柴崎 浩美,横川 彰朋
テーラーメイド医療―薬物治療の個別化― 第2版.京都廣川書店出版,2017年3月,385 pp.






Characterization of release profile of ornithine carbamoyltransferase from primary rat hepatocytes treated with hepatotoxic drugs: Implications for its unique potential as a drug-induced liver injury biomarker.
Furihata T, Aizawa T, Koibuchi A, Zhu M, Yamasaki Y, Shibuya M, Chiba K.
Drug Metab Pharmacokinet. 2016 Feb;31(1):102-105.

Establishment and characterization of a new conditionally immortalized human astrocyte cell line.
Furihata T, Ito R, Kamiichi A, Saito K, Chiba K.
J Neurochem. 2016 Jan;136(1):92-105.

Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients.
Atsukawa M, Tsubota A, Shimada N, Yoshizawa K, Abe H, Asano T, Ohkubo Y, Araki M, Ikegami T, Kondo C, Itokawa N, Nakagawa A, Arai T, Matsushita Y, Nakatsuka K, Furihata T, Chuganji Y, Matsuzaki Y, Aizawa Y, Iwakiri K.
BMC Infect Dis. 2015 Aug 19;15:344.

Cancer-type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives.
Furihata T, Sun Y, Chiba K.
Curr Drug Metab. 2015;16(6):474-85.

Differential inhibition features of direct-acting anti-hepatitis C virus agents against human organic anion transporting polypeptide 2B1.
Furihata T, Fu Z, Suzuki Y, Matsumoto S, Morio H, Tsubota A, Matsumoto S, Chiba K.
Int J Antimicrob Agents. 2015 Oct;46(4):381-8.

Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H, Abe H, Seki N, Sugita T, Aida Y, Itagaki M, Sutoh S, Shimada N, Furihata T, Tsubota A, Aizawa Y.
World J Gastroenterol. 2015 Apr 7;21(13):3904-11.


ヒトにおけるCYP3A酵素活性の評価方法 (フェノタイプ検査法)
特願2015-119065 (2015)







17th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
2019年9月 於 Foz do Iguaçu, Brazil

Simultaneous measurement of regorafenib and its metabolites in human plasma using HPLC and pharmacokinetics in Japanese patients.
H. Shibasaki-Hirano, C. Usukura, S. Katsumata, Y. Hirahara, R. Hirano, A. Yokokawa, T. Maezono, K. Kawai, M. Nishioka, T. Kobayashi, N. Okano, F. Nagashima, and J. Furuse.

The 13th International Conference on Cerebral Vascular Biology
2019年6月 於 Miami, USA

Development of a human immortalized cell-based multicellular spheroidal blood-brain barrier model: A promising platform for evaluation of permeability of various drugs.
K. Umehara, S. Izumi, N. Wakayama, T. Komori, R. Ito, K. Nunoya, Y. Yamaura, H. Imawaka, N. Anzai, H. Akita, T. Furihata.

A novel human immortalized cell-based blood-brain barrier triple co-culture model for predicting brain permeability of CNS drug candidates.
K. Kitamura, K. Umehara, R. Ito,  K. Nunoya, Y. Yamaura, H. Imawaka, S. Izumi, N. Wakayama, T. Komori,  N. Anzai, H. Akita, T. Furihata.



16th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)
2018年9月 於 Brisbane, Australia

H. Shibasaki-Hirano, A. Yamagata, M. Saito, R. Hirano, A. Yokokawa, A. Obara, K. Ishii, T. Furuta    
Measurement of plasma fluticasone propionate after multiple nasal administration

A. Yokokawa, S. Yamamoto, R. Hirano, A. Obara, K. Ishii, T. Furuta, and H. Shibasaki-Hirano    
Production of erlotinib and gefitinib metabolites via in vitro metabolism for HPLC-UV analysis


15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)

H Shibasaki-Hirano, R Adachi, A Yamagata, R Hirano, A Yokokawa, K Hosoda, A Obara, K Ishii, T Furuta    
A sensitive LC-MS/MS method for quantification of fluticasone propionatein human plasma after intranasal administration

A Yokokawa, S Kaneko, S Endo, R Hirano, F Nagashima, D Naruge, N Okano, T Kobayashi, K Kawai, J Furuse, H Shibasaki-Hirano, T Furuta    
Pharmacokinetic analysis of irinotecan and its metabolite to evaluate UGT1A1 and CYP3A activities in patients with UGT1A1 gene polymorphism

R Hirano, H Shibasaki, A Yokokawa, T Furuta    
In vivo phenotyping for CYP3A by a single-point determination of plasma concentration ratio of endogenous 6β-hydroxycortisol to cortisol



14th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT)

Hiromi Shibasaki-Hirano, Yuhei Ohomori, Noriyuki Fukawa, Akitomo Yokokawa, Fumio Nagashima, Akiyoshi Kasuga, Daisuke Naruge, Hiroshi Kitamura, Naohiro Okano, Junji Furuse, Takashi Furutad
Clinical pharmacokinetics of 3-weekly docetaxel in cancer patients 

Akitomo Yokokawa, Risa Ono, Kaori Hosoda, Kazuo Ishii, Takashi Furuta, and Hiromi Shibasaki-Hirano Separation and quantitative determination of the BCR-Abl tyrosine kinase inhibitors in human plasma by high-performance liquid chromatography with ultraviolet detection

IMG_20151013_151224.jpg IMG_20151013_124829.jpg 

EB house Research Seminar
2015年7月 Saltzburg, Austria

Tomomi Furihata
Cancer-type Organic Anion Transporting Polypeptide 1B3:Current Knowledge of the Gene Structure, Expression Profile, Functional Implications, and Research Updates





横川 彰朋,北野 彩,田中 大地,東 海,簗田 駿,清水 康平,平野 良平,古田 隆,降幡 知巳,柴崎 浩美

江間 義大、大森 悠平、府川 哲之、小栗 卓朗、横川 彰朋、降幡 知巳、柴﨑 浩美

ヒト型血液脳関門・生体模倣システムの開発 ~血液脳関門機能パラメーターによる既存モデルと新規開発モデルの比較研究~
北村 貴美子、最上 由香里、干川 和枝、A. Figarol、松崎 典弥、降幡 知巳、石田 誠一、佐藤 薫

日本薬物動態学会 第34回年会

梅原 健太、和泉 沙希、若山 直美、小森 高文、伊藤 涼、布谷 憲一、山浦 由之、今若 治夫、秋田 英万、降幡 知巳  (優秀発表賞)

北村 啓太、梅原 健太、森尾 花恵、安西 尚彦、秋田 英万、降幡 知巳  (優秀発表賞)

第36回 日本TDM学会・学術大会

第19回 遺伝子・デリバリー研究会
Development of ssPalm-based nanoparticles for suicide gene delivery into cancer cells.
Kakuta A, Furihata T, Tanaka K, Morio H, Hofbauer JP, Gruber C, Tange K, Nakai Y, Yoshioka H, Akita H.








In vitroヒト血液脳関門モデルの創薬実装を目指して:どう作り、どう使うか、私達の取り組みも踏まえて

日本食品化学学会 第24回総会・学術大会

小原 映,木下 瑞貴,細田 香織,柴崎 浩美,横川 彰朋,石井 和夫    



木下 瑞貴, 小原 映, 細田 香織, 柴崎 浩美, 横川 彰朋, 石井 和夫    
LC-MS/MS によるヒト血漿中 Equol およびその抱合 代謝物の分析法の開発と代謝物プロファイル




木下 瑞貴, 小原 映, 細田 香織, 柴崎 浩美, 横川 彰朋, 石井 和夫    



LC-MS/MS によるequol とその鏡像異性体を含む抱合代謝物の分析の検討


横浜市立大学生命環境コース 教室セミナー

血液脳関門:その構造と機能、in vitro再構築に向けた取り組み



日本薬物動態学会第31回年会 (JSSX-KASP joint symposium)

Tomomi Furihata
Cancer-type organic anion transporting polypeptide 1B3: current knowledge of expression profile, functional insights, and clinical perspectives.


平野良平,柴崎浩美,横川彰朋,古田 隆

木下瑞貴,細田 香織,小原 映,柴﨑浩美,横川彰朋,石井和夫


横川彰朋,細川真優美,平野良平,細田香織,石井和夫,柴崎浩美,古田 隆

平野良平,横川彰朋,柴崎浩美,古田 隆
血中 6β-ヒドロキシコルチゾール/血中コルチゾール濃度比に基づく 新規ヒト in vivo CYP3A 活性評価法


第30会日本薬物動態学会(JSSX-KASP joint symposium)

Tomomi Furihata.
Development of an immortalized human cell-based in vitro blood-brain barrier model and its potential applications to central nervous system drug development


横川彰朋,八郷雅弘,平野良平,細田香織,石井和夫,古田 隆,柴崎浩美
LC-MS/MSによる尿中コルチゾール及びコルチゾンの6α- / 6β-水酸化代謝物の分離定量法